Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
356.8500 -4.70 (-1.30%)
NSE Sep 04, 2025 15:31 PM
Volume: 1.2M
 

logo
Biocon Ltd.
27 Jul 2015
356.85
-1.30%
Phillip Capital
to deliver >20% earning CAGR over FY1517 led by (1) commercialisation of its Malaysia facility from Q4FY16, (2) resumption of Fidaxomicin supply contract with Merck, (3) commercial launch of Glargin (launched in Mexico and Columbia, approved in 18 other...
Biocon Ltd. has an average target of 367.20 from 5 brokers.
More from Biocon Ltd.
Recommended